Clinical Trials Using Acetylcysteine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Acetylcysteine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • A Study of N-acetylcysteine in Patients with COVID19 Infection

    This phase II trial identifies the effect of N-acetylcysteine in treating patients who have severe coronavirus disease-2019 (COVID-19) infection that does not respond to treatment (refractory) and are either patients in a critical care unit and / or are connected to a ventilator, or who are not in a critical care unit but require large amounts of supplemental oxygen. Recent studies suggest that the virus that causes COVID-19 may work by suppressing the immune system, which is the body's defense against infections and other diseases. White blood cells called lymphocytes are an important part of this defense, but recently it was found that the number of lymphocytes in a COVID-19 patient’s blood goes down as the infection gets worse and goes up as a patient gets better. N-acetylcysteine has been shown to help increase the number of lymphocytes in the blood when a virus is responsible for lowering it. This trial may help researchers determine whether N-acetylcysteine is effective enough against the virus that causes COVID-19 such that patients could leave the critical care unit or be taken off a ventilator, or could be prevented from needing ventilator support and management in a critical care unit.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Acetylcysteine for the Mitigation of Chemotherapy-Related Cognitive Impairment in Ovarian Cancer Patients Receiving Platinum-Based Therapy

    This phase I / II trial identifies the side effects and best dose of acetylcysteine and how well it works in reducing chemotherapy-related cognitive impairments in patients receiving platinum-based therapy (carboplatin or cisplatin) for ovarian cancer. Acetylcysteine is a dietary supplement that may lessen or slow down cognitive impairment such as changes in memory, attention and problem-solving. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving acetylcysteine in combination with carboplatin or cisplatin may lessen or prevent chemotherapy-related cognitive impairments in patients receiving platinum-based therapy for ovarian cancer.
    Location: UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California

  • Acetylcysteine for the Prevention of Cisplatin-Induced Hearing Loss in Children with Newly Diagnosed Localized Cancer

    This phase I trial evaluates 3 different doses of acetylcysteine (NAC) to find the best dose that may prevent inner ear damage from cisplatin in children with cancer that is newly diagnosed and has not spread to other parts of the body (localized). Permanent hearing loss is a common severe side effect in patients who receive cisplatin for cancer therapy. NAC is a drug used in children and adolescents to protect the liver and kidneys from damage caused by medicine overdoses and other toxins. NAC may also help to protect the inner ear from damage caused by cisplatin without affecting how well cisplatin kills cancer.
    Location: Children's Hospital Los Angeles, Los Angeles, California